TSE.4540
Supplementary Materials
The Third Quarter of the Term Ending March 31, 2022
February 4, 2022
TSUMURA & CO.
Consolidated Statements of Income ・・・・・ | 1 | |
Capital investments, R&D expenses, etc. ・・・・・ | 1 | |
Growth rates of 129 prescription Kampo products ・・・・・ | 1 | |
Product sales | ・・・・・ | 2 |
Consolidated Balance Sheets | ・・・・・ | 3 |
Consolidated Statements of Cash Flows ・・・・・ | 3 | |
Quarterly data | ||
Consolidated Statements of Income ・・・・・ | 4 | |
Consolidated Balance Sheets | ・・・・・ | 4 |
Consolidated Statements of Cash Flows ・・・・・ | 5 | |
Product sales | ・・・・・ | 5 |
※The 2020 results have been rearranged to the amount after applying the PPA adjustment and new accouting
Consolidated Statements of Income | (Million yen) | |||||||||||
FY 3/2021 3Q | FY 3/2022 3Q | Year-on-year | Full-year forecast for FY 3/2022 | |||||||||
cumulative | cumulative | |||||||||||
Amount | % of sales | Amount | % of sales | Amount | % | Amount | % of sales | Year-on-year | Year-on-year | |||
(Amount) | (%) | |||||||||||
Net sales | 88,444 | 100.0% | 98,382 | 100.0% | 9,938 | 11.2% | 127,500 | 100.0% | 11,086 | 9.5% | ||
Domestic | 84,579 | 95.6% | 91,317 | 92.8% | 6,737 | 8.0% | 117,800 | 92.4% | 7,746 | 7.0% | ||
Overseas | 3,864 | 4.4% | 7,065 | 7.2% | 3,200 | 82.8% | 9,700 | 7.6% | 3,339 | 52.5% | ||
Cost of sales | 41,693 | 47.1% | 47,997 | 48.8% | 6,304 | 15.1% | 61,600 | 48.3% | 5,650 | 10.1% | ||
Gross profit on sales | 46,750 | 52.9% | 50,384 | 51.2% | 3,634 | 7.8% | 65,900 | 51.7% | 5,435 | 9.0% | ||
Selling, general and administrative expenses | 29,514 | 33.4% | 31,554 | 32.1% | 2,040 | 6.9% | 44,800 | 35.1% | 3,718 | 9.1% | ||
Operating profit | 17,235 | 19.5% | 18,829 | 19.1% | 1,593 | 9.2% | 21,100 | 16.5% | 1,717 | 8.9% | ||
Ordinary profit | 17,811 | 20.1% | 21,074 | 21.4% | 3,262 | 18.3% | 23,400 | 18.4% | 2,533 | 12.1% | ||
Profit attributable to owners of parent | 13,226 | 15.0% | 15,389 | 15.6% | 2,162 | 16.4% | 16,600 | 13.0% | 1,267 | 8.3% | ||
Capital investments, R&D expenses, etc. | (Million yen) | |||||||||||
FY 3/2021 3Q | FY 3/2022 3Q | Year-on-year | Full-year forecast for FY 3/2022 | |||||||||
cumulative | cumulative | |||||||||||
Amount | % of sales | Amount | % of sales | Amount | % | Amount | % of sales | Year-on-year | Year-on-year | |||
(Amount) | (%) | |||||||||||
Capital investments | 8,386 | 9.5% | 6,716 | 6.8% | (1,670) | (19.9)% | 14,000 | 11.0% | 2,838 | 25.4% | ||
R&D expenses | 4,886 | 5.5% | 5,193 | 5.3% | 306 | 6.3% | 7,300 | 5.7% | 668 | 10.1% | ||
Advertising cost | 353 | 0.4% | 481 | 0.5% | 127 | 36.0% | 1,000 | 0.8% | 170 | 20.5% | ||
Depreciation | 5,975 | 6.8% | 6,497 | 6.6% | 521 | 8.7% | 8,500 | 6.7% | 289 | 3.5% | ||
Personnel expenses | 23,741 | 26.8% | 24,145 | 24.5% | 404 | 1.7% | 32,700 | 25.6% | 405 | 1.3% | ||
Growth rates of 129 prescription Kampo products | ||||||||||||
FY 3/2015 | FY 3/2016 | FY 3/2017 | FY 3/2018 | FY 3/2019 | FY 3/2020 | FY 3/2021 | FY 3/2022 | FY 3/2022 | FY 3/2022 | |||
1Q | 2Q | 3Q | ||||||||||
Amount | 2.4% | 2.3% | 1.9% | 2.4% | 2.7% | 1.8% | 1.1% | 7.8% | 7.7% | 7.6% | ||
Number of items with higher yen | 81 | 68 | 95 | 63 | 83 | 66 | 82 | 93 | 104 | 106 | ||
1
Product sales
(Million yen) | |||||||
FY 3/2021 | FY 3/2022 | Year-on- | Year-on- | ||||
Rank | No. | Product Name | year | year | |||
3Q | 3Q | ||||||
(Amount) | (%) | ||||||
1 | ☆ | 100 | Daikenchuto | 7,125 | 7,334 | 209 | 2.9% |
2 | ☆ | 54 | Yokukansan | 5,401 | 5,678 | 276 | 5.1% |
3 | G | 41 | Hochuekkito | 5,328 | 5,655 | 327 | 6.1% |
4 | ☆ | 43 | Rikkunshito | 5,168 | 5,548 | 380 | 7.4% |
5 | G | 17 | Goreisan | 3,426 | 4,111 | 684 | 20.0% |
6 | G | 24 | Kamishoyosan | 3,350 | 3,752 | 401 | 12.0% |
7 | G | 68 | Shakuyakukanzoto | 3,521 | 3,692 | 171 | 4.9% |
8 | ☆ | 107 | Goshajinkigan | 2,479 | 2,687 | 207 | 8.4% |
9 | 114 | Saireito | 2,387 | 2,559 | 171 | 7.2% | |
10 | G | 29 | Bakumondoto | 2,417 | 2,455 | 37 | 1.6% |
23 | ☆ | 14 | Hangeshashinto | 973 | 1,052 | 79 | 8.1% |
Total of "Drug Fostering" Program formulations | 21,148 | 22,301 | 1,153 | 5.5% | |||
Total of Growing formulations | 18,044 | 19,666 | 1,622 | 9.0% | |||
Total of 129 prescription Kampo products | 81,127 | 87,293 | 6,166 | 7.6% | |||
☆ :"Drug Fostering" Program formulations
- :Growing formulations
2
Consolidated Balance Sheets | (Million yen) | ||
As of March 31 | As of December 31, | Increase / | |
2021 | 2021 | decrease | |
Total assets | 319,063 | 338,432 | 19,368 |
Current assets | 204,273 | 221,541 | 17,268 |
Liquid assets | 109,934 | 121,193 | 11,258 |
Inventories | 80,755 | 87,217 | 6,462 |
Non-current assets | 114,789 | 116,890 | 2,100 |
Property, plant and equipment | 84,176 | 86,548 | 2,371 |
Total liabilities | 85,894 | 88,946 | 3,052 |
Current liabilities | 48,380 | 41,986 | (6,394) |
Non-current liabilities | 37,513 | 46,960 | 9,446 |
Total net assets | 233,169 | 249,485 | 16,316 |
Consolidated Statements of Cash Flows | (Million yen) | ||
FY 3/2021 | FY 3/2022 | Year-on-year | |
3Q | 3Q | ||
Cash flows from operating activities | 12,706 | 17,815 | 5,108 |
Cash flows from investing activities | (4,975) | (7,510) | (2,534) |
Cash flows from financing activities | (9,708) | (5,192) | 4,515 |
Cash and cash equivalents at the end of the quarter | 59,051 | 67,070 | 8,019 |
3
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Tsumura & Co. published this content on 04 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 February 2022 06:25:09 UTC.